

5



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 014058-002940US

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On September 5, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Jill R. Clarke
Jill R. Clarke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SRIRAM *et al.*

Application No.: 10/078,075

Filed: February 15, 2002

For: VACCINATION WITH PEPTIDE
OF MHC CLASS II MOLECULES FOR
TREATMENT OF AUTOIMMUNE
DISEASE

Examiner: Not yet assigned

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed July 5, 2002, Applicants submit that the computer-readable form in the instant application is identical with the Substitute Sequence Listing filed in Application No. 09/286,274, filed September 25, 2000. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/286,274 as the computer-readable form for the instant application. The information in